Publisher： Bentham Science Publishers
E-ISSN： 1873-4286|8|17|1527-1545
ISSN： 1381-6128
Source： Current Pharmaceutical Design, Vol.8, Iss.17, 2002-08, pp. : 1527-1545
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.
Related content
Computational Methods in the Discovery and Design of BACE-1 Inhibitors
Current Medicinal Chemistry, Vol. 19, Iss. 36, 2012-12 ,pp. :
Access to resources
Recommend
